{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:32:36Z","timestamp":1792816356995,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Frank Sanderse Stichting"},{"DOI":"10.13039\/501100005040","name":"Bontius Stichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.trim.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T11:22:56Z","timestamp":1560511376000},"page":"101209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft"],"prefix":"10.1016","volume":"57","author":[{"given":"Floris C.","family":"Loeff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther H.M.","family":"van Egmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.A.R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa","family":"Wijnands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Von Dem Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Jedema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantijn J.M.","family":"Halkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.trim.2019.06.001_bb0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbmt.2010.02.005","volume":"16","author":"Miller","year":"2010","journal-title":"Biol Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.trim.2019.06.001_bb0010","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","article-title":"Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited","volume":"36","author":"Deol","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.trim.2019.06.001_bb0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14712598.2011.554811","article-title":"Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Roddie","year":"2011","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"4","key":"10.1016\/j.trim.2019.06.001_bb0020","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3324\/haematol.2013.089565","article-title":"Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation","volume":"99","author":"Eefting","year":"2014","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.trim.2019.06.001_bb0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bmt.2013.111","article-title":"Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL","volume":"49","author":"Eefting","year":"2014","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.trim.2019.06.001_bb0030","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V62.4.873.873","article-title":"Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement","volume":"62","author":"Hale","year":"1983","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.trim.2019.06.001_bb0035","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.bbmt.2013.10.001","article-title":"Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag)","volume":"19","author":"Novitzky","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.trim.2019.06.001_bb0040","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders","volume":"100","author":"Perez-Simon","year":"2002","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.trim.2019.06.001_bb0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/146532401753174025","article-title":"In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation","volume":"3","author":"Kottaridis","year":"2001","journal-title":"Cytotherapy."},{"issue":"3","key":"10.1016\/j.trim.2019.06.001_bb0050","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","article-title":"Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen","volume":"99","author":"Chakraverty","year":"2002","journal-title":"Blood."},{"issue":"25","key":"10.1016\/j.trim.2019.06.001_bb0055","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1182\/blood-2010-01-265413","article-title":"HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning","volume":"115","author":"Mead","year":"2010","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.trim.2019.06.001_bb0060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2015.136846","article-title":"Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion","volume":"101","author":"Eefting","year":"2016","journal-title":"Haematologica."},{"issue":"8","key":"10.1016\/j.trim.2019.06.001_bb0065","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/sj.bmt.1705119","article-title":"Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts","volume":"36","author":"Novitzky","year":"2005","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.trim.2019.06.001_bb0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease","volume":"9","author":"Lee","year":"2003","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.trim.2019.06.001_bb0075","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0301-472X(00)00677-9","article-title":"Acute graft-vs-host disease: pathobiology and management","volume":"29","author":"Goker","year":"2001","journal-title":"Exp. Hematol."},{"issue":"5","key":"10.1016\/j.trim.2019.06.001_bb0080","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2002-02-0377","article-title":"Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery","volume":"100","author":"Chakrabarti","year":"2002","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.trim.2019.06.001_bb0085","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.trim.2019.06.001_bb0090","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.4049\/jimmunol.1701018","article-title":"High mutation frequency of the PIGA gene in T cells results in reconstitution of GPI anchor(\u2212)\/CD52(\u2212) T cells that can give early immune protection after Alemtuzumab-based T cell-depleted allogeneic stem cell transplantation","volume":"200","author":"Loeff","year":"2018","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.trim.2019.06.001_bb0095","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/bmt.2010.308","article-title":"Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia","volume":"46","author":"Spyridonidis","year":"2011","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.trim.2019.06.001_bb0100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2008.07184.x","article-title":"Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia","volume":"142","author":"Tholouli","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.trim.2019.06.001_bb0105","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.bbmt.2009.08.002","article-title":"A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation","volume":"15","author":"Bertz","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"10.1016\/j.trim.2019.06.001_bb0110","first-page":"1559","article-title":"Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab","volume":"91","author":"von dem Borne","year":"2006","journal-title":"Haematologica."},{"issue":"4","key":"10.1016\/j.trim.2019.06.001_bb0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation."},{"issue":"1\u20132","key":"10.1016\/j.trim.2019.06.001_bb0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-1759(01)00556-7","article-title":"Pharmacokinetics of CAMPATH-1H: assay development and validation","volume":"260","author":"Rebello","year":"2002","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"10.1016\/j.trim.2019.06.001_bb0125","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.exphem.2008.11.002","article-title":"Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors","volume":"37","author":"Nijmeijer","year":"2009","journal-title":"Exp. Hematol."},{"issue":"9","key":"10.1016\/j.trim.2019.06.001_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1281411","article-title":"Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors","volume":"58","author":"Loeff","year":"2017","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"10.1016\/j.trim.2019.06.001_bb0135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Prog. Biomed."},{"issue":"1","key":"10.1016\/j.trim.2019.06.001_bb0140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput. Methods Prog. Biomed."},{"issue":"2","key":"10.1016\/j.trim.2019.06.001_bb0145","first-page":"224","article-title":"Prediction of blood volume in normal human adults","volume":"51","author":"Nadler","year":"1962","journal-title":"Surgery."},{"issue":"2","key":"10.1016\/j.trim.2019.06.001_bb0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.trim.2019.06.001_bb0155","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1128\/JCM.42.4.1498-1504.2004","article-title":"Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection","volume":"42","author":"Kalpoe","year":"2004","journal-title":"J. Clin. Microbiol."},{"issue":"1","key":"10.1016\/j.trim.2019.06.001_bb0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease","volume":"12","author":"Tabrizi","year":"2010","journal-title":"AAPS J."},{"issue":"3","key":"10.1016\/j.trim.2019.06.001_bb0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.bmt.1705049","article-title":"Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletion","volume":"36","author":"Garland","year":"2005","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.trim.2019.06.001_bb0170","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/asheducation-2017.1.693","article-title":"Graft versus tumor effects and why people relapse","volume":"2017","author":"Falkenburg","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"Suppl. 1","key":"10.1016\/j.trim.2019.06.001_bb0175","first-page":"S27","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag')","volume":"21","author":"von dem Borne","year":"2009","journal-title":"Curr. Opin. Oncol."},{"issue":"12","key":"10.1016\/j.trim.2019.06.001_bb0180","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bmt.1705385","article-title":"Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath \"in the bag\" as T-cell depletion: the Leiden experience","volume":"37","author":"Barge","year":"2006","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.trim.2019.06.001_bb0185","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/jjco\/hyw146","article-title":"Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia","volume":"47","author":"Ishizawa","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.trim.2019.06.001_bb0190","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2125.2007.02914.x","article-title":"Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response","volume":"64","author":"Mould","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.trim.2019.06.001_bb0195","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood."},{"issue":"16","key":"10.1016\/j.trim.2019.06.001_bb0200","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2010-05-286856","article-title":"Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution","volume":"116","author":"Chakraverty","year":"2010","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.trim.2019.06.001_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039416","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"Rao","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.trim.2019.06.001_bb0210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/146532401317070899","article-title":"Pharmacokinetics of CAMPATH-1H in BMT patients","volume":"3","author":"Rebello","year":"2001","journal-title":"Cytotherapy."},{"issue":"1","key":"10.1016\/j.trim.2019.06.001_bb0215","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2002-09-2687","article-title":"Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications","volume":"102","author":"Morris","year":"2003","journal-title":"Blood."},{"issue":"6162","key":"10.1016\/j.trim.2019.06.001_bb0220","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327419300413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327419300413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:58:58Z","timestamp":1760810338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327419300413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":44,"alternative-id":["S0966327419300413"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2019.06.001","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101209"}}